PFIZER INC (PFE)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$1,760.0M
Cash & Equivalents
$2,615.0M
Quarterly Burn Rate
$149,382M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (10 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
BEVACIZUMAB-BVZR
ZIRABEV |
APPROVED | Abscess, Acromegaly, Acute Exacerbation of Psychosis, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Adolescent, Advanced Breast Cancer, Advanced Gastric Cancer, Advanced/Metastatic Non-Small Cell Lung Cancer, Alzheimer's Disease, Angina, Aspergillosis, Asthma, Atopic Dermatitis, ATTR-PN, Bacterial Infection, Bipolar Disorder, BK Nephropathy, BK Viremia, Brain and Central Nervous System Tumors, Breast Cancer, Breast Cancer Recurrent, Breast Neoplasms, Candidemia, Carcinoma, Hepatocellular, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Cellulitis, Cervical Pain, Child, Child, Preschool, Chronic Lymphocytic Leukemia, Clear Cell Renal Cell Carcinoma, Colorectal Adenocarcinoma, Colorectal Cancer, Colorectal Neoplasms, Complicated Intra-abdominal Infection, Complicated Urinary Tract Infection, Complication, Delirium, Delusional Disorder, Depression, Diabetes Mellitus, Type 1, Encephalitis, Tick-Borne, Epilepsies, Partial, Esophagitis, Familial Amyloid Polyneuropathy, Gastrointestinal Stromal Tumor, |
|
RITUXIMAB-PVVR
RUXIENCE |
APPROVED | — |
|
NICOTINE
NICOTROL |
APPROVED | — |
|
ADALIMUMAB-AFZB
ABRILADA |
APPROVED | — |
|
IRINOTECAN HYDROCHLORIDE
CAMPTOSAR |
APPROVED | — |
|
ELRANATAMAB
ELREXFIO |
APPROVED | — |
|
MARSTACIMAB-HNCQ
HYMPAVZI |
APPROVED | — |
|
EPIRUBICIN HYDROCHLORIDE
ELLENCE |
APPROVED | — |
|
INFLIXIMAB-QBTX
IXIFI |
APPROVED | — |
|
TRASTUZUMAB-QYYP
TRAZIMERA |
APPROVED | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.